Lv51
1010 积分 2021-06-29 加入
天津市呼吸道合胞病毒单克隆抗体在预防接种门诊的推动和实施
13天前
已完结
天津市呼吸道合胞病毒单克隆抗体在预防接种门诊的推动和实施
16天前
已完结
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study
19天前
已完结
Strategies to optimize duration of immunotherapy in advanced NSCLC: Current evidence and future directions
19天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
28天前
已完结
新生儿和婴儿呼吸道合胞病毒致急性下呼吸道感染临床特征和疾病负担
28天前
已完结
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
30天前
已完结
Overcoming Primary and Acquired Resistance to Immunotherapy in Non-Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies
1个月前
已关闭
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
1个月前
已完结
Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs
1个月前
已完结
皖公网安备34019202002308
